Pink Sheet is part of the Informa Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Australian Provisional Approval Pathway To Get Tough On Sponsors Upfront

Executive Summary

Plans by Australia’s Therapeutic Goods Administration to develop a provision approval pathway for drugs have moved up a gear.


Related Content

Australia’s 150-Day Priority Review Pathway Set For July Kick-Off
No Delays Expected As Australian Bill On Faster Drug Approvals Goes To Parliament
Australia Consults On 150-Day Priority Review, Provisional Approval
EU Conditional Approval Should Be A Drug Development Tool, Not A Rescue Remedy





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts